Concepedia

Author

Jindřich Fínek

Charles UniversityORCID

Also Known As

Finek J, J Finek, J Fínek, J. FINEK, J. Finek, J. Fínek, JINDRICH FINEK, JINDŘICH FÍNEK, Jindrich Finek, Jindrich Fínek

282

Publications

2K

Citations

24

H-Index

34

Concepts

All Affiliations

Charles UniversityMasaryk UniversityMasaryk Memorial Cancer InstituteGenomacThomayer University Hospital
JF

About

Jindřich Fínek is an author at Charles University specializing in medicine, oncology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

239

2

Cell Biology

2

2

80

3

Immunology

2

2

49

4

Health Sciences

1

1

32

5

Orthopaedics

1

1

32

Jindřich Fínek

×

67

Publications

1.6K

Citations

24

H-Index

YearCitations

Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease.

J Šafránek, Martin Pešta, L Holubec,

PubMed

2009

70

Cancer Incidence and Mortality in the Czech Republic

Ladislav Dušek, Denisa Malúšková, Ondřej Májek,

Klinicka onkologie

2014

69

The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer

Ondřej Fiala, Miloš Pešek, Jindřich Fínek,

Cancer Genetics

2013

61

Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib

Ondřej Fiala, Miloš Pešek, Jindřich Fínek,

Neoplasma

2016

61

Cancer epidemiology in Central and South Eastern European countries

Eduard Vrdoljak, Marek Z. Wojtukiewicz, Tadeusz Pieńkowski,

Croatian Medical Journal

2011

60

G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab

Ondřej Fiala, Tomáš Büchler, Beatrice Mohelníková-Duchoňová,

Tumor Biology

2015

54

18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation.

Jiří Ferda, Eva Ferdová, Milan Hora,

PubMed

2013

50

A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer.

Jindřich Fínek, L Holubec, Tomáš Svoboda,

PubMed

2009

43

Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples.

Martin Pešta, L Holubec, Ondřej Topolčan,

PubMed

2005

40

Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.

Ondřej Fiala, Miloš Pešek, Jindřich Fínek,

PubMed

2014

39

Page 1